drugset
drugset / Trial / NCT03082235

Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E6742 in Healthy Adult Subjects

NCT03082235 ↗

Phase 1 Completed 72 enrolled Eisai Inc.
RandomizedParallel-groupTriple-blindBasic science

Summary

Study E6742-A001-001 is a randomized, double-blind, placebo-controlled, single ascending dose study conducted to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single ascending oral doses of E6742 in healthy adult participants.

Timeline

Start
2017-03-03
Primary completion
2017-10-11
Completion
2017-10-11

Drugs

EvaluationDrugModalityDoseRoute
Subject E6742 Unknown 10 mg Oral
Subject E6742 Unknown 25 mg Oral
Subject E6742 Unknown 50 mg Oral
Subject E6742 Unknown 100 mg Oral
Subject E6742 Unknown 200 mg Oral
Subject E6742 Unknown 400 mg Oral
Subject E6742 Unknown 800 mg Oral

Indications

No indication recorded.